Thomas W. Campi, DVM, MPVM is CEO and co-founder of Modulant Biosciences, a new biotech company focusing on antivirals for pets and livestock.  Their current pipeline includes an antiviral for cats suffering from FIP and an antiviral for pigs infected with the PRRS virus.  They also have a One Drug for All Cancers platform.

Tom is a veterinarian and is board certified by the American College of Poultry Veterinarians. He has extensive experience in drug development, regulatory affairs and technology evaluation.   Dr. Campi’s career spans 35 years and includes leadership roles in regulatory, research and technology acquisitions at Elanco, and Head of Research and Regulatory Affairs at Huvepharma. He was also a founder and partner in Reliance Animal Health Partners and Covenant Animal Health Partners.

Tom received his veterinary degrees from the University of California, Davis.

• Why PRRS continues to cost the industry over $1 billion a year, even with vaccines in play.
• How a new treatment stops the virus after infection by blocking capsid assembly.
• Why this antiviral tech could work across PRRS strains and avoid resistance.
• What a one-shot solution could mean for producers aiming to stay PRRS-free.
• Tom’s “golden nugget”